China Meheco Group (SHSE:600056) Investors Are Sitting on a Loss of 20% If They Invested a Year Ago
China Meheco Group (SHSE:600056) Investors Are Sitting on a Loss of 20% If They Invested a Year Ago
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by China Meheco Group Co., Ltd. (SHSE:600056) shareholders over the last year, as the share price declined 21%. That's well below the market decline of 10%. On the other hand, the stock is actually up 17% over three years.
购买指数基金可以轻松匹配整体市场回报。 虽然个别股票可能会赢得大赢家,但更多的股票无法产生令人满意的回报。 在过去一年中,中国医药股份有限公司(SHSE:600056)股东们就实现了这一下行风险,股价下跌了21%,远低于市场下跌的10%。 另一方面,股票实际上上涨了17%,而且是在过去三年内。上涨6.3%的三年中,股票的价格似乎没有反映出EPS的增长。所以,有理由对一些其他指标进行研究。在不幸的12个月期间,其中中国医药的股价下跌,它的每股收益(EPS)实际上提高了22%。 过去的增长预期可能过于不合理。 鉴于收益率相当低,只有1.9%,我们对分红在阐明股价方面的作用表示怀疑。 相反,收入下降了16%是一个真正的问题。 许多投资者认为,收入下降很可能是降低收益的先驱,因此这可能很好地解释了股价的疲软。
So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.
那么我们来看看这家公司的长期表现是否符合其业务进展情况。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
虽然有效市场假说仍然被一些人教授,但被证明市场是过度反应的动态系统,投资者并不总是理性的。检查市场情绪如何随时间变化的一种方法是看一个公司的股价与其每股收益(EPS)之间的交互作用。
During the unfortunate twelve months during which the China Meheco Group share price fell, it actually saw its earnings per share (EPS) improve by 22%. It's quite possible that growth expectations may have been unreasonable in the past.
鉴于CEO的薪酬少于类似公司的中位数,这可能值得注意。 但是,虽然CEO薪酬始终值得检查,但真正重要的问题是该公司能否在未来增长收益。 如果您想进一步调查股票,可以从中国医药的收益,收入和现金流的这份自由互动报告开始。
It's fair to say that the share price does not seem to be reflecting the EPS growth. So it's well worth checking out some other metrics, too.
公允地说,股价似乎并未反映出每股收益的增长。因此,值得检查一些其他指标。
Given the yield is quite low, at 1.9%, we doubt the dividend can shed much light on the share price. In contrast, the 16% drop in revenue is a real concern. Many investors see falling revenue as a likely precursor to lower earnings, so this could well explain the weak share price.
我们遗憾地报告,中国医药的股东们在今年下跌了20%(包括分红)。 不幸的是,这比更广泛的市场下跌的10%更糟。 话虽如此,不可避免地会有一些股票在下跌的市场中被过度抛售。 关键是注意基本面发展。 长期投资者不会那么沮丧,因为在五年内,他们每年可以获得4%的回报。 如果基础数据继续表明长期可持续增长,当前的抛售可能是值得考虑的机会。 虽然值得考虑市场条件对股价的不同影响,但还有其他更重要的因素。 例如,我们发现了3个关于中国医药的警告信号(其中1个可能很严重!)在此投资之前,您应该意识到这些。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的图表显示了收益和营收随时间的变化情况(通过单击图像揭示确切的值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240527/0-e4c809659f3c81091c6a878e2869c87c-0-b7565c6c12c227f7237eec55081344d0.png/big)
It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. This free interactive report on China Meheco Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
这可能值得注意的是,CEO的薪酬低于类似规模公司的中位数。 但是,尽管CEO的薪酬始终值得检查,但真正重要的问题是该公司能否在未来实现收益增长。 如果您想进一步调查该股,本免费互动报告可以从中国医药的收益,收入和现金流开始,这是一个很好的起点。
A Different Perspective
不同的观点
We regret to report that China Meheco Group shareholders are down 20% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 10%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 4%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 3 warning signs for China Meheco Group (1 is potentially serious!) that you should be aware of before investing here.
长期投资者不会那么沮丧,因为在五年内,他们每年可以获得4%的回报。 如果基础数据继续表明长期可持续增长,当前的抛售可能是值得考虑的机会。 虽然值得考虑市场条件对股价的不同影响,但还有其他更重要的因素。 例如,我们发现了3个关于中国医药的警告信号(其中1个可能很严重!)在此投资之前,您应该意识到这些。
For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找获胜投资的人来说,最近有内部购买的低估公司免费列表可能是一个很好的选择。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。